What to Know About Moderna's Insider Selling
It's not surprising for top executives and board members to sell some of their shares in a company from time to time. Most shareholders don't begrudge a modest level of such activity, but when insiders sell too much, it can cause concerns.
Some investors might have such worries about Moderna (NASDAQ: MRNA) right now. The biotech reported 17 insider sale transactions in August. So far this month, it's reported seven insider sale transactions. That's an average of nearly one insider sale per trading day over the last six weeks.
Should you be worried? Here are three things you'll want to know about Moderna's insider selling.
Source Fool.com
